首页> 外文期刊>Pain. >Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia.
【24h】

Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia.

机译:与外消旋体相比,曲马多对映体的镇痛效果和安全性:一项随机,双盲的妇科患者随机双盲研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The opioid analgesic tramadol is a racemate and consists of 50% (+)- and 50% (-)-enantiomer. This study investigated analgesic efficacy and safety of both enantiomers after intravenous (i.v.) injection in comparison with the racemate. Ninety-eight patients recovering from major gynaecological surgery under opioid-free halothane anaesthesia were treated in a randomised, double-blind study with (+)-tramadol, (-)-tramadol or the racemate. Following an individualised i.v. loading dose up to a maximum of 200 mg, patient-controlled analgesia with demand doses of 20 mg was made available for 24 h. The primary criterion was of efficacy was the decrease of pain intensity on a 5-point verbal rating scale from severe or maximum pain to mild or no pain intensity on a 5-point verbal rating scale from severe or maximum pain to mild or no pain within the first hour after the loading dose. The secondary criterion was patient satisfaction with pain relief during the 24-h observation period stated in the final interview. Patients who terminated the study prematurely were evaluated as non-responders. Of patients treated with (+)-tramadol, tramadol racemate, and (-)-tramadol, 12%, 15%, and 53% of treated patients, respectively, terminated the study prematurely because of inefficacy. Of patients treated with (+)-tramadol, racemate or (-)-tramadol 67%, 48% and 38%, respectively, were considered responders regarding the primary criterion of efficacy (P = 0.061), and 82%, 76%, or 41% with respect to the secondary criterion (P = 0.001). Assessment of laboratory screening, adverse events, vital signs and blood gas monitoring showed no serious drug-related events. Nausea and vomiting were the most frequently reported non-serious side effects and were most often seen with (+)-tramadol. Taking into account both efficacy and safety aspects, the racemate seems to be superior to either enantiomer alone.
机译:阿片类镇痛曲马多是外消旋体,由50%(+)-和50%(-)-对映体组成。这项研究调查了与外消旋体相比,静脉内(i.v.)注射后两种对映体的止痛效果和安全性。在无阿片类药物氟烷麻醉下从大妇科手术中恢复的九十八名患者接受了(+)-曲马多,(-)-曲马多或消旋体的随机双盲研究。跟随个性化的i.v.负荷最大剂量为200 mg,患者自控镇痛,需求剂量为20 mg,持续24小时。主要的疗效标准是:在5点语言评分量表上,疼痛强度从严重或最大疼痛降低至轻度或无疼痛;在5点语言评分量表上,疼痛强度从严重或最大疼痛降低至轻度或最大疼痛。加载剂量后的第一个小时。次要标准是患者在最终访谈中所述的24小时观察期内对疼痛缓解的满意度。提前终止研究的患者被评估为无反应者。在接受(+)-曲马多,曲马多消旋体和(-)-曲马多治疗的患者中,分别有12%,15%和53%的治疗患者由于无效而提前终止研究。在疗效的主要标准方面,分别接受(+)-曲马多,消旋体或(-)-曲马多治疗的患者分别被认为有反应者(P = 0.061),82%,76%,48%和38%,或次要标准的41%(P = 0.001)。实验室筛查,不良事件,生命体征和血气监测的评估显示没有严重的药物相关事件。恶心和呕吐是最常见的非严重副作用,最常见于(+)-曲马多。考虑到功效和安全性方面,外消旋体似乎优于任何一种对映体。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号